PMID- 36118637 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220920 IS - 2364-3722 (Print) IS - 2196-9736 (Electronic) IS - 2196-9736 (Linking) VI - 10 IP - 9 DP - 2022 Sep TI - Gel immersion endoscopic submucosal dissection: clinical experience with 13 cases of superficial esophageal cancer. PG - E1302-E1306 LID - 10.1055/a-1894-0719 [doi] AB - Esophageal endoscopic submucosal dissection (ESD) of tumors located on the gravity side is technically challenging. Given that gel immersion ESD (GIESD) is performed by immersing lesions in gel, we hypothesized that it could be used to eliminate the disadvantage associated with submerging the gravity side. Here, we performed GIESD using VISCOCLEAR for superficial esophageal cancer on the gravity side of the esophagus, with monopolar devices. This study aimed to evaluate the short-term outcomes of GIESD for superficial esophageal cancer. Fifteen patients with 16 superficial esophageal cancers underwent GIESD by a single operator, and 13 cases were evaluated. All patients were male, and GIESD was performed in the middle (12/13, 92.3 %) and lower (1/13, 7.7 %) thoracic esophagus. The lesions were located on the left (7/13, 53.8 %), posterior (5/13, 38.5 %), and right (1/13, 7.7 %) esophageal walls. The median procedure time was 27 minutes (interquartile range [IQR], 14-68), and the median dissection speed was 20 mm (2) /min (IQR, 14-25.7). The median amount of gel used was 400 mL (IQR, 360-580), and no gel-related adverse events were observed. The median total dose of midazolam was 3 mg (IQR, 2-5). GIESD was completed with en bloc and R0 resections achieved in 100 % of the 13 cases. Delayed adverse events, such as bleeding or perforation, did not occur (0/13, 0 %). CI - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). FAU - Nakano, Yuya AU - Nakano Y AD - Department of Gastroenterology, Saitama Medical University International Medical Center, Saitama, Japan. FAU - Tashima, Tomoaki AU - Tashima T AD - Department of Gastroenterology, Saitama Medical University International Medical Center, Saitama, Japan. FAU - Jinushi, Ryuhei AU - Jinushi R AD - Department of Gastroenterology, Saitama Medical University International Medical Center, Saitama, Japan. FAU - Terada, Rie AU - Terada R AD - Department of Gastroenterology, Saitama Medical University International Medical Center, Saitama, Japan. FAU - Mashimo, Yumi AU - Mashimo Y AD - Department of Gastroenterology, Saitama Medical University International Medical Center, Saitama, Japan. FAU - Kawasaki, Tomonori AU - Kawasaki T AD - Department of Pathology, Saitama Medical University International Medical Center, Saitama, Japan. FAU - Uraoka, Toshio AU - Uraoka T AD - Department of Gastroenterology and Hepatology, Graduate School of Medicine, Gunma University, Gunma, Japan. FAU - Ryozawa, Shomei AU - Ryozawa S AD - Department of Gastroenterology, Saitama Medical University International Medical Center, Saitama, Japan. LA - eng PT - Journal Article DEP - 20220914 PL - Germany TA - Endosc Int Open JT - Endoscopy international open JID - 101639919 PMC - PMC9473821 COIS- Competing interests The authors declare that they have no conflict of interest. EDAT- 2022/09/20 06:00 MHDA- 2022/09/20 06:01 PMCR- 2022/09/01 CRDT- 2022/09/19 04:14 PHST- 2022/02/25 00:00 [received] PHST- 2022/07/04 00:00 [accepted] PHST- 2022/09/19 04:14 [entrez] PHST- 2022/09/20 06:00 [pubmed] PHST- 2022/09/20 06:01 [medline] PHST- 2022/09/01 00:00 [pmc-release] AID - 10.1055/a-1894-0719 [doi] PST - epublish SO - Endosc Int Open. 2022 Sep 14;10(9):E1302-E1306. doi: 10.1055/a-1894-0719. eCollection 2022 Sep.